Deprenyl and the Issue of Neuroprotection
Bibliographic record
Abstract
The Parkinson Disease Study Group (PDSG) recently published its findings concerning antioxidant drug thera py for early Parkinson's disease [ 1 ] (idiopathic parkinson ism (IP)) as follow-up to an earlier report published in 1989 [2], After almost 4 years of controversy [3,4], the sole firm conclusion that could be drawn concerning the use of deprenyl, a monoamine oxidase (MAO) type B inhibitor was that it allowed the introduction of levodopa treatment to be postponed by somewhat less than 1 year.For this reason, the authors argue, deprenyl should be considered among the available therapeutic options for the initial treatment of early Parkinson's disease.A dis cussion of when and how symptomatic treatment of early Parkinson's disease should be carried out is beyond the scope of this editorial and has recently been addressed elsewhere [5], Our discussion here will be restricted to the issue of neuroprotection as illustrated by the D A TA TO P experience.Few would argue against neuroprotection being a goal worth pursuing.Flowever, for the concept to be meaning fully assessed a specific definition is required.On the cel lular level, the definition of neuroprotection is relatively straightforward.Most would accept an agent as neuroprotective if it reduced the death rate in a population of cells.In this context, visual examination of cells surviving in culture, following a toxic stressor, would allow conclu sions regarding the neuroprotective effect of an agent.In experiments where neuropathological studies can be per formed serially, for example in an experimental group of animals, comments concerning cellular neuroprotection can likewise be made.In this context, experimental mod els can be constructed, based on knowledge of a given del eterious phenomenon, including its mechanisms and nat ural evolution, and potential neuroprotective influences proposed (e.g.MPTP-induced parkinsonism -oxidative F .Vingcrhoeis.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.006 | 0.012 |
| Meta-epidemiology (narrow) | 0.004 | 0.001 |
| Meta-epidemiology (broad) | 0.005 | 0.002 |
| Bibliometrics | 0.002 | 0.001 |
| Science and technology studies | 0.002 | 0.002 |
| Scholarly communication | 0.005 | 0.004 |
| Open science | 0.003 | 0.002 |
| Research integrity | 0.018 | 0.024 |
| Insufficient payload (model declined to judge) | 0.005 | 0.005 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".